Cargando…
Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
The addition of rabbit anti-human thymocyte globulin (ATG) to the conditioning regimen prior to allogeneic hematopoietic cell transplantation has significantly reduced the risk of graft-versus-host disease (GvHD) and graft failure. However, ATG has a small therapeutic window. Overexposure of ATG pos...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005072/ https://www.ncbi.nlm.nih.gov/pubmed/32030538 http://dx.doi.org/10.1208/s12248-020-0419-6 |
_version_ | 1783494854854049792 |
---|---|
author | Amrani, Mohsin El Admiraal, Rick Willaert, Lobke Ebskamp-van Raaij, Lysette J. C. Lacna, Amelia M. Hack, C. Erik Huitema, Alwin D. R. Nierkens, Stefan van Maarseveen, Erik M. |
author_facet | Amrani, Mohsin El Admiraal, Rick Willaert, Lobke Ebskamp-van Raaij, Lysette J. C. Lacna, Amelia M. Hack, C. Erik Huitema, Alwin D. R. Nierkens, Stefan van Maarseveen, Erik M. |
author_sort | Amrani, Mohsin El |
collection | PubMed |
description | The addition of rabbit anti-human thymocyte globulin (ATG) to the conditioning regimen prior to allogeneic hematopoietic cell transplantation has significantly reduced the risk of graft-versus-host disease (GvHD) and graft failure. However, ATG has a small therapeutic window. Overexposure of ATG post-HCT hampers T cell immune reconstitution and has been associated with increased relapse rates and viral reactivations, whereas underexposure has been associated with an increased incidence of GvHD, both of which lead to increased mortality. Therapeutic drug monitoring of T cell binding ATG plasma levels provides a means to optimize dosing for patients at high risk for graft failure to ensure timely T cell immune reconstitution and subsequently increase survival chances. This manuscript describes the first liquid chromatography tandem-mass spectrometry (LC-MS/MS) method to quantify the pharmacologically active fraction of polyclonal ATG in plasma. This was achieved through immunoaffinity purification of active ATG from plasma with Jurkat T cells. After the binding and washing, samples were eluted, denatured, and trypsin-digested. Signature peptides originating from the IgG constant chain were measured with LC-MS/MS. Critical method parameters were optimized, and the method was successfully validated following European Medicines Agency (EMA) guidelines. The method covered the therapeutic range of ATG and was validated at a lower limit of quantification (LLOQ) of 1 AU/mL with an overall CV and bias of 11.8% and − 2.5%, respectively. In conclusion, we developed a LC-MS/MS-based method to quantify active polyclonal rabbit ATG in human plasma. We suggest that this novel assay can be used to monitor and optimize dosing of ATG in clinical practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1208/s12248-020-0419-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7005072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-70050722020-02-25 Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry Amrani, Mohsin El Admiraal, Rick Willaert, Lobke Ebskamp-van Raaij, Lysette J. C. Lacna, Amelia M. Hack, C. Erik Huitema, Alwin D. R. Nierkens, Stefan van Maarseveen, Erik M. AAPS J Research Article The addition of rabbit anti-human thymocyte globulin (ATG) to the conditioning regimen prior to allogeneic hematopoietic cell transplantation has significantly reduced the risk of graft-versus-host disease (GvHD) and graft failure. However, ATG has a small therapeutic window. Overexposure of ATG post-HCT hampers T cell immune reconstitution and has been associated with increased relapse rates and viral reactivations, whereas underexposure has been associated with an increased incidence of GvHD, both of which lead to increased mortality. Therapeutic drug monitoring of T cell binding ATG plasma levels provides a means to optimize dosing for patients at high risk for graft failure to ensure timely T cell immune reconstitution and subsequently increase survival chances. This manuscript describes the first liquid chromatography tandem-mass spectrometry (LC-MS/MS) method to quantify the pharmacologically active fraction of polyclonal ATG in plasma. This was achieved through immunoaffinity purification of active ATG from plasma with Jurkat T cells. After the binding and washing, samples were eluted, denatured, and trypsin-digested. Signature peptides originating from the IgG constant chain were measured with LC-MS/MS. Critical method parameters were optimized, and the method was successfully validated following European Medicines Agency (EMA) guidelines. The method covered the therapeutic range of ATG and was validated at a lower limit of quantification (LLOQ) of 1 AU/mL with an overall CV and bias of 11.8% and − 2.5%, respectively. In conclusion, we developed a LC-MS/MS-based method to quantify active polyclonal rabbit ATG in human plasma. We suggest that this novel assay can be used to monitor and optimize dosing of ATG in clinical practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1208/s12248-020-0419-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-02-06 /pmc/articles/PMC7005072/ /pubmed/32030538 http://dx.doi.org/10.1208/s12248-020-0419-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Amrani, Mohsin El Admiraal, Rick Willaert, Lobke Ebskamp-van Raaij, Lysette J. C. Lacna, Amelia M. Hack, C. Erik Huitema, Alwin D. R. Nierkens, Stefan van Maarseveen, Erik M. Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry |
title | Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry |
title_full | Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry |
title_fullStr | Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry |
title_full_unstemmed | Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry |
title_short | Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry |
title_sort | quantification of t cell binding polyclonal rabbit anti-thymocyte globulin in human plasma with liquid chromatography tandem-mass spectrometry |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005072/ https://www.ncbi.nlm.nih.gov/pubmed/32030538 http://dx.doi.org/10.1208/s12248-020-0419-6 |
work_keys_str_mv | AT amranimohsinel quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT admiraalrick quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT willaertlobke quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT ebskampvanraaijlysettejc quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT lacnaameliam quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT hackcerik quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT huitemaalwindr quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT nierkensstefan quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry AT vanmaarseveenerikm quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry |